Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Markets will remain closed on April 17, 2024 on account of Ram Navami.

Indian share markets open firm
Fri, 6 Dec 09:30 am

Asian stock markets have opened the day on a mixed note with Indonesia (down 0.8%) and Singapore (down 0.4%) leading the losses. However, markets in Japan (up 0.4%) and Taiwan (up 0.3%) are trading firm. The Indian equity markets indices have opened the day on a positive note. Stocks in the banking and capital goods space are leading the gains.

The Sensex today is up by around 77 points (0.4%), while the NSE-Nifty is up by around 24 points (0.4%). Mid and small cap stocks are also trading in the green with the BSE Mid Cap and BSE Small Cap indices up by around 0.5% and 0.3% respectively. The rupee is currently trading at Rs 61.75 to the US dollar.

Steel stocks have opened the day on a mixed note with Steel Authority of India Ltd (SAIL) and Bhushan Steel leading the losses. However, Tata Sponge Iron Ltd and Adhunik Metaliks are trading firm. As per a leading financial daily, SAIL has reported total sales volume of 9.7 lakh tonnes for the month of November 2013. This is 10% higher than the sales volumes in the corresponding month of the previous financial year. The company's exports witnessed a three-fold year-on-year (YoY) jump in volumes with shipments to the tune of 61,000 tonnes during November 2013. Total export volume for the period April-November 2013 stood at 3.2 lakh tonnes, higher by 72% YoY.

Indian pharma stocks have opened the day on a firm note with Orchid Chemicals, Piramal Enterprises, Strides Arcolab and Ranbaxy Laboratories leading the gains. As per a leading financial daily, Cipla's wholly owned subsidiary Cipla Holding B.V. has acquired 100% stake in Croatia-based firm Celeris d.o.o. It must be noted that Celeris is the distributor of Cipla's products in Croatia. The company has not disclosed the financial figures pertaining to the acquisition. The acquisition of Celeris is in line with the company's aim to establish a platform to market its products. Given that Celeris is a ready-made platform for the company, it would be particularly beneficial for launching respiratory drugs in Europe.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets open firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.